SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-044326
Filing Date
2023-12-11
Accepted
2023-12-11 08:45:18
Documents
19
Period of Report
2023-12-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 56862
2 ex10-1.htm EX-10.1 87509
3 ex10-2.htm EX-10.2 54260
4 ex99-1.htm EX-99.1 32898
5 ex10-1_001.jpg GRAPHIC 18110
6 ex10-2_001.jpg GRAPHIC 38932
7 ex99-1_001.jpg GRAPHIC 4208
  Complete submission text file 0001493152-23-044326.txt   523350

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE rspi-20231206.xsd EX-101.SCH 3018
9 XBRL LABEL FILE rspi-20231206_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE rspi-20231206_pre.xml EX-101.PRE 22361
12 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3080
Mailing Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452
Business Address 126 VALLEY ROAD SUITE C GLEN ROCK NJ 07452 (201) 444-4947
RespireRx Pharmaceuticals Inc. (Filer) CIK: 0000849636 (see all company filings)

IRS No.: 330303583 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-16467 | Film No.: 231477014
SIC: 2834 Pharmaceutical Preparations